Loading institutional data...
Loading institutional data...
Institutional distribution: ownership decreased -1.90% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M 100.0% | $35.0M 100.0% | $200.5M 100.0% | $38.6M 100.0% | $54.7M 100.0% | $46.0M 100.0% | $42.6M 100.0% | $15.6M 100.0% | $14.8M 100.0% | $475 100.0% |
| Cost of Revenue | $5.0M 76.6% | $22.0M 62.9% | $166.9M 83.2% | $26.8M 69.4% | $39.4M 72.1% | $30.6M 66.6% | $26.5M 62.2% | $9.7M 62.4% | $7.5M 50.7% | $211 44.4% |
| Gross Profit | $1.5M 23.4% | $13.0M 37.1% | $33.6M 16.8% | $11.8M 30.6% | $15.3M 27.9% | $15.4M 33.4% | $16.1M 37.8% | $5.9M 37.6% | $7.3M 49.3% | $264 55.6% |
| Research & Development | — | $100K 0.3% | — | $100K 0.3% | $500K 0.9% | $500K 1.1% | $100K 0.2% | — | — | — |
| Selling, General & Admin | $12.9M 197.9% | $19.0M 54.2% | $55.1M 27.5% | $24.4M 63.3% | $35.4M 64.8% | $28.5M 62.0% | $34.5M 81.0% | $19.8M 127.0% | $6.1M 41.0% | $528K 111189.7% |
| Total Operating Expenses | $12.9M 197.9% | $19.0M 54.2% | $88.2M 44.0% | $33.0M 85.4% | $54.0M 98.9% | $32.6M 71.0% | $43.4M 102.0% | $42.2M 270.8% | $12.5M 84.2% | $528K 111189.7% |
| Operating Income | -$11.4M -174.6% | -$6.0M -17.1% | -$54.6M -27.2% | -$21.2M -54.9% | -$38.8M -71.0% | -$17.3M -37.6% | -$27.3M -64.2% | -$36.3M -233.2% | -$5.2M -34.9% | -$528K -111134.1% |
| Interest Expense | $628K 9.6% | $467K 1.3% | $5.4M 2.7% | $1.4M 3.5% | $551K 1.0% | — | $9.2M 21.6% | $700K 4.5% | $868K 5.9% | $533K 112190.9% |
| Other Income (Expense), net | -$2.8M -42.3% | $5.8M 16.6% | $618K 0.3% | -$1.6M -4.1% | -$551K -1.0% | $20.7M 45.0% | -$32.0M -75.2% | -$148.1M -951.0% | -$868K -5.9% | -$587K -123583.4% |
| Pretax Income | -$8.6M -132.2% | -$159K -0.5% | -$60.7M -30.3% | -$22.8M -59.0% | -$39.3M -72.0% | $3.4M 7.4% | -$59.3M -139.3% | — | — | -$1.1M -234717.5% |
| Income Tax Expense | — | $9K 0.0% | -$71K -0.0% | $2K 0.0% | -$18K -0.0% | $37K 0.1% | $0 0.0% | $0 0.0% | — | $0 0.0% |
| Net Income | -$45.0M -688.8% | -$168K -0.5% | -$43.1M -21.5% | -$22.8M -59.0% | -$39.3M -71.9% | $3.4M 7.4% | -$59.3M -139.3% | -$184.5M -1184.2% | -$6.0M -40.8% | -$3.0M -621225.1% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.13 | $-0.10 | $-1.95 | $-32.29 | $-58.93 | $0.15 | $-7.26 | — | — | — |
| EPS (Diluted) | $-2.13 | $-0.10 | $-1.95 | $-32.29 | $-58.93 | $0.14 | $-7.26 | — | — | — |
| Weighted Avg Shares (Basic) | 21.1M | 1.6M | 22.1M | 705K | 667K | 19.9M | 8.2M | — | — | 3.0M |
| Weighted Avg Shares (Diluted) | 21.1M | 1.6M | 22.1M | 705K | 667K | 21.9M | 8.2M | — | — | 3.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -11058%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $1M covers the $0 due within a year 1309000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2022-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Top 19 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-18
Where each multiple sits in its own 9-yr range · 18th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 9-yr history.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 62.4 | 62.2 | 66.6 | 72.1 | 69.4 | 83.2 | 62.9 | 76.6 |
| Gross Profit | 37.6 | 37.8 | 33.4 | 27.9 | 30.6 | 16.8 | 37.1 | 23.4 |
| R&D | — | 0.2 | 1.1 | 0.9 | 0.3 | — | 0.3 | — |
| SG&A | 127.0 | 81.0 | 62.0 | 64.8 | 63.3 | 27.5 | 54.2 | 197.9 |
| Operating Income | -233.2 | -64.2 | -37.6 | -71.0 | -54.9 | -27.2 | -17.1 | -174.6 |
| Income Tax | 0.0 | 0.0 | 0.1 | -0.0 | 0.0 | -0.0 | 0.0 | — |
| Net Income | -1184.2 | -139.3 | 7.4 | -71.9 | -59.0 | -21.5 | -0.5 | -688.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SRXH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| SRXH | $42M | — | — | 6.4× | -81.3% | 23.4% | -689% | -11058% | -11058% | 0.0× | 19 |
Peers = companies sharing SRXH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.